Research Focus

Former Employee. Research Facilities; Non-Stipend SKI

Recent additions – View all

1. Phase 2 trial of (177)Lutetium (Lu-177) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (Lu-177-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)

   Meeting Abstract

   Morris, M. J.; Milowsky, M. I.; Pandit-Taskar, N.; Divgi, C.; David, K. A.; Rozario, C. P.; Vallabhajosula, S.; Goldsmith, S. J.; Scher, H. I.; Nanus, D. M.
   Journal of Clinical Oncology (2006)

   Fulltext@MSK | Save
2. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen

   Journal Article

   Bander, N. H.; Trabulsi, E. J.; Kostakoglu, L.; Yao, D.; Vallabhajosula, S.; Smith-Jones, P.; Joyce, M. A.; Milowsky, M.; Nanus, D. M.; Goldsmith, S. J.
   Journal of Urology (2003)

   Fulltext@MSK | Save
3. The utility of monoclonal antibodies in the imaging of prostate cancer

   Journal Article

   Yao, D.; Trabulsi, E. J.; Kostakoglu, L.; Vallabhajosula, S.; Joyce, M. A.; Nanus, D. M.; Milowsky, M.; Liu, H.; Goldsmith, S. J.
   Seminars in Urologic Oncology (2002)

   Fulltext@MSK | Save